just watching the other companies in this sector highlights what a rare beast this one is. most are trying to get through long expensive trials, or looking for partners to assist moving forawd.
whilst many have bright prospects the punters are a bit gun shy of their prospects. PXS and CXS have given a few thrills. so has MSB .
PYC has a unique business model, with so much interest from big pharma for their Library of Phylomers the financial rewards are built into the business model much earlier.
The risks are reduced. The market is waking up to PYC's approach.
This is a safe way to get BIO exposure whilst maintaining the potential upside.
Once the three deals which have been flagged by the company have been formally signed we will be abble to put a more solid valuation on the is little company. that valuation should be on an international basis.
a rare beast.
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.005(5.00%) |
Mkt cap ! $489.9M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 11.0¢ | 10.0¢ | $358.4K | 3.354M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 130000 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 2500 | 1 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
10.5¢ |
Change
0.005 ( 1.16 %) |
||||
| Open | High | Low | Volume | ||
| 10.5¢ | 11.0¢ | 10.0¢ | 1085435 | ||
| Last updated 15.58pm 03/05/2024 ? | |||||
| PYC (ASX) Chart |